Nachrichten zur Inventiva S.A. Aktie

Inventiva announces a €20.1 million issuance of royalty certificates

Daix (France), Long Island City (New York, United States), July 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva”…

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position

Daix (France), Long Island City (New York, United States), July 5, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or…

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

Daix (France), Long Island City (New York, United States), May 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a…

Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript

…

Inventiva: share price falls, phase III recruitment suspended

Inventiva fell sharply on the stock market on Friday morning, following the announcement of the suspension of recruitment for its…

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

Daix (France), Long Island City (New York, United States), February 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the…

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

…

Inventiva reports 9M results

…

Inventiva S.A. (IVA) Q2 2023 Earnings Analyst Call Transcript

…

Inventiva reports its 2023 first-half financial results and provides a corporate update

Daix (France), Long Island City (New York, United States), September 28, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the…

Inventiva and Hepalys Pharma to develop and commercialize Lanifibranor in Japan and South Korea

…

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

…

Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

...…

Form 6-K Inventiva S.A. For: Jul 27

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

...…

Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

Daix (France), Long Island City (New York, United States), June 24, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a…

Where Inventiva Stands With Analysts

Latest Ratings for IVA DateFirmActionFromTo Nov 2021HC Wainwright & Co.MaintainsBuy Sep 2021HC Wainwright & Co.MaintainsBuy Mar 2021Societe GeneraleDowngradesBuySell …

Inventiva jumps 25% after mid-stage data for NASH candidate

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Inventiva, Gossamer top healthcare gainers; IO Biotech, agilon among losers

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Pre-market Movers: EAST, CNVS, DRIO, AGRX, Inventiva.

ROMANEL-SUR-MORGES (dpa-AFX) - The following are some of the stocks making big moves in Wednesdays pre-market trading (as of 07.05…

Inventiva ADRs Soar 30% Post-Market Following Positive Results From Phase 2 Study

Inventiva ADRs Soar 30% Post-Market Following Positive Results From Phase 2 Study...…

Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD

Daix (France), Long Island City (New York, United States), June 13, 2022 –Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage…

Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023

Daix (France), Long Island City (New York, United States), June 7, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage…

Form 6-K Inventiva S.A. For: May 26

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China

...…

Form 6-K Inventiva S.A. For: May 25

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Inventiva reports Q1 results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 6-K Inventiva S.A. For: May 16

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update

Daix (France), Long Island City (New York, United States), May 16, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the…

Form 6-K Inventiva S.A. For: May 05

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 6-K Inventiva S.A. For: May 04

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Combined General Meeting of May 25, 2023. Availability of the preparatory documents

Daix (France), Long Island City (New York, United States), May 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a…

Form 6-K Inventiva S.A. For: Apr 17

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 6-K Inventiva S.A. For: Mar 29

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Inventiva GAAP EPS of -€1.31 misses by €0.02, revenue of €12.18M misses by €0.44M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Inventiva reports its 2022 full-year results

...…

Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results

Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the…

Inventiva started at buy with $27 stock price target at Stifel Nicolaus

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Correction: Inventiva reports preliminary financial results for Full-Year 2022¹

Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the…

Form 6-K Inventiva S.A. For: Feb 14

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Inventiva reports preliminary financial results for Full-Year 2022¹

Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the…

Form 6-K Inventiva S.A. For: Jan 06

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis

...…

dpa-AFX ProFeed